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Abstract
Gliomas represent the most common primary malignant 
brain tumors in adults, with an extremely poor prognosis. 
Among several risk factors, lifestyle was also recently 
identified as a major risk factor for the development of 
primary glioma. In the present study, we explore the 
relationship between obesity and glioma in a cellular model. 
Thus, we have study the influence of adipocytes secretome 
on glioma cell line GL261. Using the 3T3-L1 adipocyte 
cell line, and its conditioned medium (adipokines-enriched 
medium), we showed that adipocyte-released factors relate 
with glioma angiogenic, growth, hormones and metabolic 
behavior by MALDI-TOF-MS and proteomic array analysis. 
In a first view, STI1, hnRNPs and PGK1 are under expressed 
on CGl. Similarly, both carbonic anhydrase and aldose 
reductase are even suppressed in glioma cells that grown 
under adipokines-enriched environment. Contrariwise, 
RFC1, KIF5C, ANXA2, N-RAP and RACK1 are 
overexpressed in GL261 cell the in the presence of the 
adipokines-enriched medium. We further identified the 
factors that are released by adipocyte cells, and revealed that 
several pro-inflammatory and angiogenic factors, such as 
IL-6, IL-11, LIF, PAI-1, TNF-α, endocan, HGF, VEGF IGF-
I, were secreted to the medium into a high extent, whereas 
TIMP-1 and SerpinE1 were under expressed on CGl. This 
study discloses an interesting in vitro model for the study of 
glioma biology under a Bobesity^ environment, that can be 
explored for the understanding of cancer cells biology, for 
the search of biomarkers, prognostic markers and therapeutic 
approaches.
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Introduction
Gliomas, a wide term which comprises all tumors arising from
the supportive tissue of the brain, represent 30% of all brain
tumors and 80% of all malignant brain tumors. They are the
most common primary malignant brain tumors in adults
(Parkin et al. 2002; Ostrom et al. 2014). Prognosis is extremely
poor, with a median survival time of approximately 12 to
15 months and is almost invariably fatal (Patrick and Kesari
2008). This tumor represents about 12–15% of all primary
brain tumors and about 60–75% of all astrocytomas. Gliomas
increase in frequency with age, and affect preferentially men
(Patrick and Kesari 2008; Chen et al. 2012; Huse et al. 2013).
Genetic factors in glioma etiology are poorly understood; less
than 5% of glioma cases are familial in origin, with only a few
described by rare genetic syndromes (Bainbridge et al. 2014).
Gliomas are heterogeneous and are typically classified accord-
ing to World Health Organization tumor grade, and also clas-
sified on the basis of cellular lineage: astrocytic, oligodendrog-
lial, and mixed tumors (Luisa et al. 2012).
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In 2001, different studies from the International Agency for
Research into Cancer (IARC) and the World Cancer Research
Fund (WCRF) have reported a relationship and established a
link between obesity and cancer risk (Roberts et al. 2010;
Khandekar et al. 2011). Excess adiposity is related with an
increase the incidence and/or death rates from a wide variety
of human cancers, being the most common colon, rec-
tum, esophagus, kidney, pancreas, gallbladder, ovary,
cervix, liver, prostate and certain hematopoietic cancers
(Pi-Sunyer 2002; Calle and Thun 2004; Roberts et al.
2010; Prieto-Hontoria et al. 2011; Khandekar et al. 2011).
Overweight and obesity are important risk factors for devel-
oping cancer and also for cancer related mortality (van
Kruijsdijk et al. 2009; Wolin et al. 2010). It is important to
understand the pathophysiological mechanisms involved in
the link between obesity and cancer, in order to target future
preventive and therapeutic strategies for cancer in obese
people (van Kruijsdijk et al. 2009).
Despite its high morbidity, the etiology of glioma remains
largely unknown. Among several risk factors, lifestyle was
also recently identified as a major risk factor for the develop-
ment of primary glioma (Benson et al. 2008). Consequently,
there might be a relationship between the increase and dys-
function of adipose tissue. Obesity, favored by the modern
lifestyle, acquired epidemic proportions nowadays, and accel-
erated weight gain, in adults, is associated with increasing
incidence of all central nervous system tumors, mostly glioma
(Young and Van Brocklyn 2007). At the present time, it
is not clear which factors might be involved in this
relation. Genes that influence obesity are highly expressed in
the brain and could also mediate glioma susceptibility
(Benson et al. 2008; Moore et al. 2009). Some studies ana-
lyzed body weight in relation to survival in glioma demon-
strating higher death rates in patients with an excess body
weight (Siegel et al. 2013). Obesity, and in particular visceral
obesity, plays a major role in the pathogenesis of sev-
eral metabolic disorders (Calle et al. 1999). Recently
two large sample studies have established that obesity
has no clear relationship with the occurrence of glioma
(Wiedmann et al. 2017; Disney-Hogg et al. 2018).
Development of obesity is also associated with substantial
modulation of adipose tissue (AT) structure, involving adipo-
genesis, angiogenesis, and extracellular matrix remodeling
(Costa et al. 2004; Lijnen 2008). Thus, AT can trigger blood
vessel formation, and in turn AT endothelial cells promote
pre-adipocyte differentiation. Angiogenesis, the physio-
logical process involving the growth of new blood ves-
sels from existing vasculature, plays a central role in
growth and development of both normal and malignant
tissues (Costa et al.; Carmeliet 2003). Angiogenesis is
required for AT expansion, as well as for cancer pro-
gression and metastization (Costa et al. 2007). Anti-
angiogenic therapy has been a widely used strategy to fight
tumor growth, and recently has also been acknowledged as a
potential therapeutic intervention for obesity (Costa et al.
2007; Pirraco et al. 2010).
Furthermore, and concerning lipid diet content, evidence
demonstrates that lipid metabolism is dysregulated in obesity
and there might be a common pathway between excess nutri-
ents and inflammation to increased metabolic risk (Young and
Van Brocklyn 2007; Yin et al. 2008). Increase in lipolysis in
AT leads to elevation in free fatty acids (FFA) in plasma and
contribute to fat deposition in liver and skeletal muscle, which
may promote systemic insulin resistance through several
mechanisms, such as induction of oxidative stress through
incomplete oxidation and inflammatory responses. However,
the cause of the adipocyte malfunction remains to be identi-
fied in obesity(Yin et al. 2008).
AT is also recognized by its endocrine function as producer
of biological mediators (van Kruijsdijk et al. 2009;Wolin et al.
2010). There are several cytokines regarding cell proliferation,
angiogenesis, cytoskeletal rearrangement and survival. Some
receptors and signaling pathways associated have revealed to
stimulate growth and invasiveness capacity of glioma cells,
whereas others have been correlated to glioma cell prolifera-
tion blockage (Young and Van Brocklyn 2007; van Kruijsdijk
et al. 2009; Roberts et al. 2010). The mechanisms underlying
the associations between energy balance and cancer risk
should be clarified.
The present study aims to develop an in vitro rodent model
for the study of the influence of adipokines secreted by adi-
pose tissue in glioma biology. We propose a model in which
GL261 cells, a mouse glioma cell line, is cultured in the pres-
ence or absence of 3T3-L1 mature adipocytes conditioned
medium. The 3T3-L1 pre-adipocytes were differentiated un-
der controlled experiments and the adipokines and inflamma-
tion chemokines pattern expression were examined by prote-
ome microarrays in the mature adipocytes conditioned medi-
um were grown.
Materials and methods
The protein expression was accessed by means of
bidimensional polyacrylamide gel electrophoresis under dena-
tured conditions (2D-PAGE) followed by mass spectrometry
analysis of the interest spot. The spots were analyzed by
matrix assisted laser desorption ionization time-of-flight/
mass spectrometry (MALDI-TOF-MS). The non-
conditioned glioma cells served as the control group
for the conditioned glioma cells. We have used the ma-
ture adipocytes secreted adipokines (secretome) and
enriched the GL261 medium, followed by analysis of
the proteins on GL261 on a 2-dimensional proteomic
gel approach, so different spots could be studied by
means of mass spectroscopy.
Chemicals
The reagents acetonitrile, iodoacetamide (IAA), dl-
dithiothreitol (DTT) (99%w/w) and trypsin from porcine pan-
creas (proteomics grade) were purchased from Sigma
(Steinheim, Germany). Formic acid puriss for mass spectrom-
etry (≥98%), ammonium bicarbonate (>99.5% w/w) and the
matrix assisted laser desorption ionization MALDI matrix α-
Cyano-4-hydroxycinnamic acid (α-CHCA) puriss for
MALDI-MS were from Fluka (Buchs, Switzerland).
Trifluoroacetic acid (TFA, 99% v/v) was from Riedel-de-
Haën (Seelze, Germany). ProteoMass Peptide MALDI-MS
Calibration Kit (MSCAL2) from Sigma was used as mass
calibration standard for MALDI-TOF-MS.
Cell culture
For the current work 3T3-L1 (purchased from American Type
Culture Collection) and GL-261 (gently given by Prof.
Pedroso Lima, CNC, Coimbra, Portugal) mouse cell lines
were used. 3T3-L1 and GL-261 cells were cultured in
DMEM (Dulbecco’s Modified Eagle’s Medium with 4.5 g/L
Glucose & L-Glutamine, without Sodium Pyruvate. Santa
Cruz Biotechnology, Inc.), supplemented with 10% FBS,
and 1000 units/mL gentamycin solution, maintained in T-25
tissue culture flasks in 5% CO2/95% air at 37 °C in a humid-
ified incubator.
Adipocyte differentiation and conditioned medium
collection
3T3-L1 pre-adipocytes were propagated and allowed to
reach confluence. After 2 days (day 0), the differentia-
tion was initiated by addition of a hormonal mixture
composed of 2 μM insulin, 1 μM dexamethasone and
0.25 mM isobutylmethylxanthine. Three days after (day
3), the induction medium was replaced by complete me-
dium supplemented with insulin only. At day 6 cultures
were washed twice in phosphate buffered saline and
incubated in serum-free medium. After 24 h (day 7),
medium was harvested from the adipocytes cultures,
spun for 3000 g for 5 min and the supernatant (mature
adipocytes conditioned medium) was stored at −80 °C
for the subsequent treatments. This conditioned medium
is rich in adipokines which are globally referred as
secretome.
Afterwards, Glioma cells were divided in two distinct
groups. On one hand, glioma cells GL-261 were grown under
the influence of the mature adipocytes secretome were desig-
nated conditioned glioma cells (CGl). On the other hand, the
control group consisted in the glioma cells cultured in the
absence of 3T3-L1 conditioned medium and was designated
as non-conditioned glioma cells (NCGl).
Sample preparation for 2D-PAGE
Sample preparation for 2D-PAGEwas performed according to
published procedures with minor modifications (Verpelli et al.
2010). The cells were manual detached from the flask and
were mechanically lysed at 4 °C in lysis solution [CHAPS
4%, 5 mM Tris, pH 8.8, 0.05% protease inhibitor cocktail
(Sigma)] using a glass potter, and the samples were centri-
fuged at 2000 g for 15 min at 4 °C in order to eliminate
aggregates. The protein concentrations in each sample were
measured by means of a DC Bio-Rad assay. A total of 900 mg
of protein from each sample was precipitated with cold ace-
tone and resuspended in thiourea buffer (7 M urea, 2 M thio-
urea 2% CHAPS, 2% ASB14, 5% glycerol, 40 mM DTT,
4 mM TCEP, 1% 3–10 IPG buffer, Amersham), and the sam-
ples were mixed overnight at 4 °C in the dark and clarified by
centrifugation at 16000 g for 15 min at 4 °C. The supernatant
was first separated by isoelectric focusing over a pH range of
3–10 using precast first-dimension drystrip 3–10 NL 11 cm
(Bio-Rad) following a multi-step protocol for 90,000 Vht
(Protean IEF Cell, BioRad). The first-dimension strip was
equilibrated in 50 mM Tris, pH 8.8, 6 M urea, 30% glycerol,
2% SDS plus 16 mM DTT for 20 min, and then plus 25 mM
iodioacetamide for 15 min, and loaded on a midi format
(11 cm) 9–16% acrylamide gel to separate the proteins by
molecular weight. Second-dimension runs were performed
using BioRad Midi Cell at 30 V 1 h, 300 V 4 h at a constant
temperature of 18 °C. Protein spots were revealed using
home-made blue Coomassie staining, and the gel images were
acquired by means of an Image scanner at 300 DPI resolution
and analyzed using Image2D Master Platinum software (both
from Amersham).
At least three gels per condition were included in the anal-
ysis. Normalized spot volume values were studied using SPSS
software version 13.0 for statistical analysis (SPSS Inc.). In
brief, the data for each spot match set were analyzed using a
box-plot test in order to eliminate outliers, a K-S test to check
normal distribution, an F test to analyze the variance, and
finally Student’s T test to compare the mean values, which
were considered significant for a P value cut off of 0.01.
In-gel protein digestion
In-gel digestion of the excised proteins with trypsin was per-
formed according to published procedures with minor modi-
fications (Rosenfeld et al. 1992; Shevchenko et al. 2006;
Gundry et al. 2009). Protein spots were destained for 10 min
with a solution of acetonitrile 50% (v/v) in 25 nM NH4HCO3
and mixed vigorously using a vortex. After removal of the
destaining solution, gel pieces were washed with water for
10 min using vigorous vortexing. This step was repeated
twice. Afterwards, the gel pieces were dehydrated in acetoni-
trile for 10 min, which was then removed, and the gel pieces
were placed to dry in a vacuum centrifuge. Reduction of pro-
tein disulfide bonds was performed with a solution 10 mM of
dithiotreitol (DTT) in 25 mMNH4HCO3, for 15 min at 60 °C.
After cooling to room temperature for about 15 min, the DTT
solution was replaced with a solution 110 mM of
iodoacetamide (IAA) in 25 mM NH4HCO3. Incubation with
the alkylation agent was performed for 35 min at room tem-
perature in the dark. After reduction and alkylation steps, the
gel pieces were submitted once more to the washing and de-
hydration procedure with water and acetonitrile, in the same
way as described above. Subsequently, the gel pieces were
completely dried in a vacuum centrifuge. The dried protein
spots were incubated with a solution of trypsin 25 ng/μL in
12.5 mMNH4HCO3 in an ice bath for 30 min to rehydrate the
gel and to allow enzyme penetration into it. In-gel protein
digestion was performed at 37 °C overnight. After collecting
the supernatant to clean vials, further peptide extraction was
performed by addiction of a solution of trifluoroacetic acid
0.1% (v/v) in acetonitrile 50% (v/v) to the gel pieces and
incubation at room temperature with shaking for 10 min.
This step was repeated twice. All extracts were pooled and
evaporated to dryness. The samples were re-suspended with
10 μL of trifluoroacetic acid 0.1% (v/v).
MALDI-TOF-MS analysis
Prior toMALDI analysis, the sample was mixed with an equal
volume of theMALDImatrix solution, 10mg/mlα–CHCA in
trifluoroacetic acid 0.1% (v/v) and acetonitrile 50% (v/v). An
aliquot of the sample/matrix solution (0.5 μL) was hand-
spotted onto the MALDI sample plate and the sample was
allowed to dry. The mass spectrometric analyses were per-
formed using the Applied Biosystems MALDI-TOF-MS sys-
tem model Voyager-DE PRO Biospectrometry Workstation
equipped with a nitrogen laser radiating at 337 nm (Applied
Biosystems, Foster City, USA) and the laser intensity was set
just above the threshold for ion production. MALDI mass
spectra were acquired in positive ion reflectron mode, with
an accelerating voltage of 20 kV, a grid voltage of 15 kV,
0.4 V of guide wire and an ion extraction delay of 100 ns.
The MS spectra for each sample were based on the average
of 700 laser shots per spot with an acquisition rate of 2 ns. MS
acquisition data was calibrated externally using the
ProteoMass Peptide MALDI-MS Calibration Kit.
Data analysis and database searching
All data were processed using DataExplorer 4.5 software from
Applied Biosystems. Peptide Mass Fingerprint (PMF) data
were used to search for candidate proteins using the
MASCOT database search (http://www.matrixscience.com)
engine. SwissProt database was selected by default for all
Mascot searches. NCBInr database was used each time no
significant identification was obtained with SwissProt.
Database searches were, by default, performed with no
taxonomy restriction and allowing up to a maximum peptide
mass tolerance of 100 ppm. The number of allowed missed
cleavages for trypsin was set to one. Carbamidomethylation of
cysteine and methionine oxidation were selected as fixed and
variable modifications, respectively. In order to provide
accurate results, protein identification was considered
positive for MASCOT protein scores higher than 77 (p < 0.
01) that present a minimum of 4 peptides matching.
Proteome profiler™ array assay
Determination of relative levels of pre-selected mouse
adipokines in conditioned and non-conditioned GL261 cell
cultures was performed by using Mouse Adipokine Array
Kit (R&D Systems Europe, UK). Cells were rinsed with
PBS before Lysis Buffer solubilization at, approximately,
1 × 107 cells/mL. Then, they were resuspended and rocked
at 4 °C for 30 min, following a microcentrifugation at
14,000 x g for 5 min. After supernatant transfer into a clean
test tube, proteins were quantified a total protein assay. Array
Procedure was performed according to manufacture instruc-
tions (Catalogue Number ARY024). Data analysis was based
on pixel densities on developed X-ray film collected and an-
alyzed using Gel-Doc XR (Bio-Rad© Laboratories), acquired
by Image Lab Software 5.2.1 (Bio-Rad© Laboratories) then
quantified by ImageJ 1.49 (NIH, USA).
Computational biology databases and in silico cancer
signaling analysis
In order to analyze the relationship between the charac-
teristics of glioma cells and molecules secreted by adi-
pocytes we have used The Cancer Genome Atlas
(TCGA) and REATOME to further evaluate the expression
of molecular pattern profiles.
TCGA is a collaboration between the National Cancer
Institute (NCI) and the National Human Genome Research
Institute (NHGRI) with comprehensive, multi-dimensional in-
formation of fundamental genomic changes in 33 types of
cancer. Regarding TCGA, we have inquired the Brain Lower
Grade Glioma cohort (TCGA-LGG project, n = 516) database
from Research Network (www.cancergenome.nih.gov).
We have also upload the orthologs genes coding for the
referred proteins into REACTOME (https://reactome.org/) to
screen their involvement in human glioma cancer cells. This
platform can be used to interpret the results of high-
throughput experimental genomic studies and by systems bi-
ologists to building up predictive models of normal and dis-
ease variant pathways (Fabregat et al. 2018). Reactome path-
way, reaction andmolecules pages extensively cross-reference
to over 100 different online bioinformatics resources,
including NCBI Gene, Ensembl and UniProt databases, the
UCSC Genome Browser, ChEBI small molecule databases,
and the PubMed literature database.
Statistical analysis
The differences in expression of proteins between glioma me-
dium and CGl by Proteome Profile Microarray were analyzed
by 2-way ANOVA for multiple comparisons with Prism
Graphpad. P values of <0.05 were considered statistically sig-
nificant. MALDI-TOF-MSwas conducted by T-test at P value
cut off of 0.1 using default parameters with Prism Graphpad.
Results and discussion
In order to understand which adipocyte secreted proteins po-
tentially influenced glioma tumor behavior, we analyzed the
protein expression of glioma cells conditioned medium ob-
tained from adipocytes cultures, by means of bidimensional
polyacrylamide gel electrophoresis under denatured condi-
tions (2D-PAGE) followed by mass spectrometry analysis of
the selected spots. These spots were analyzed by matrix
assisted laser desorption ionization time-of-flight/mass spec-
trometry (MALDI-TOF-MS). The non-conditioned glioma
cells (NCGl) were used as the control group for the condi-
tioned glioma cells (CGl).
Differentially expressed proteins
Eleven differentially expressed spots were identified among
the 1192 matched protein spots. Its detailed information is
presented in Table 1.
The 5 over-expressed proteins found on the CG1 cells.
RFC1 corresponds to spot-1 with 9.38 isoelectric point,
126,705 relative molecular mass and presenting a 2.32 ratio.
KIF5C corresponds to spot-2, with 5.86 isoelectric point,
109,777 relative molecular mass and 2.91 ratio. ANXA2 cor-
responds to a spot-3 protein spot, with 7.55 isoelectric point,
38,937 relative molecular mass and 2.23 ratio. NRAP, corre-
sponds to spot-4, with 9.34 isoelectric point, 196,716 relative
molecular mass and 2.82 ratio. RACK 1, corresponds to spot-
5, with 7.60 isoelectric point, 35,511 relative molecular mass
and 2.07 ratio (Table 1). The 3 spots significantly under-
expressed in CGl corresponding to 3 proteins identified as
follows: STI1, corresponds to spot-6 and it presents a 6.4
isoelectric point, 63,170 relative molecular mass and 0.33 ra-
tio; hnRNP L, corresponds to spot-7 spot, with 8.33 isoelectric
point, 64,550 relative molecular mass and 0.66 ratio; PGK1,
corresponding to spot-8, with 8.02 isoelectric point, 44,921
relative molecular mass and 0.4 ratio.
Only 2 spots were present in NCGl control group were
Aldose Reductase, corresponds to spot-9, with 6.71 isoelectric
point, 36,052 relative molecular mass, and carbonic
anhydrase, corresponds to spot-10, with 6.45 isoelectric point,
30,124 relative molecular mass.
The only spot present in the CGl was Citrate Synthase that
corresponds to spot-11, with 8.72 isoelectric point and 51,988
of relative molecular mass.
Expression proteomic profile of GL261 conditioned
medium
Intending to further elucidate the involvement of adipose
secretome in glioma, we evaluated the profile of GL261 under
conditioned medium (CGL). The medium proteome is a de-
sirable sample due to their accessibility and representability
due, in part, to the wide dynamic range of protein concentra-
tions, which lead to the discovery of new protein markers
(Fig. 1).
As illustrated in Fig. 1 different secretion patterns of nu-
merous growth-factors, adipokines, cytokines and
angiogenesis-related molecules, were found between the dif-
ferent media. Endocan, IGFBPs, FGF acidic, vascular endo-
thelial growth factor (VEGF), among many others were found
upregulated in GL-261 conditioned medium. Nevertheless, a
significant reduction in adiponectin, serpin E1 and TIMP-1
levels were observed in CGl (p ≤ 0.01).
Conclusion
Adipose tissue is defined as a lipid store depot, inflammatory
and endocrine organ (Mendonça and Soares 2015). Thus, it
provides a chronic low-grade inflammatory condition poten-
tiated by the presence of multiple cytokines and hormones,
sometimes associated with disease. Most part of these factors
are known to play a role in cell proliferation, apoptosis, mi-
gration and invasiveness, as well as adhesion capacity, becom-
ing expected to be overexpressed in conditioned medium.
Recent findings point that inflammatory, angiogenic or meta-
bolic factors, significantly influence tumor behavior (Hanahan
and Weinberg 2011; Coelho et al. 2015). Taking into account
in one hand the morbidity and the mortality associated to
gliomas and on the other hand the increased prevalence of
obesity and its possible role in cancer, studies that elucidate
this relationship are of paramount importance in order
to identify new glioma biomarkers, to grade specific
protein signatures to provide treatment efficacy, and to
identify novel effective drug targets against malignant glioma
(Niclou et al. 2010).
In the current study we analyzed the proteome profile of a
cellular model of brain cancer GL261 under the presence of
adipocyte secretome. Our general results suggest an increase
of viability, metabolic fitness, proliferation of tumor cell and
reduced apoptosis. However, we are going to approach it by
focusing on their relationship within inflammation and
angiogenesis.
The proteomic analysis has allowed the identification of
eleven well differentiated proteins that are secreted by 3T3-
L1 adipocytes with a potential role in cancer biology. The
molecular, biochemical and physiological characteristics of
the differentially expressed proteins are summarized in
Table 1.
Our findings revealed lower expression of STI1, hnRNP L
and PGK1 when glioma cells were exposed to mature adipo-
cytes conditioned medium. Regarding multiple effects of
STI1, hnRNPs and PGK1 this under expression might reflect
that the adipokines secreted by mature adipocytes might be
able to stop some important pathways in carcinogenesis,
complemented with remodeling the oxidative metabolism to-
ward the utilization of fatty acids substrates instead of glucose.
Table 1 Results retrieved for MALDI-TOF-MS/PMF queries in Mascot database search engine. Differential protein expression (> 2.0 fold up-
regulated and < 0.5-fold down-regulated in CGl/NCGl) of a total of 192 protein spots
Protein spot MascotMOWSE
score a
N matches
(n queries)
% sequence
coverageb
Ratioc Protein ID Function
Spot-1d 69 14 (43) 14 2.32 (↑) Replication factor C
subunit (RFC1)
Clamp loader in eurcarioric replication. Role
in maintaining the stability and the
integrity of the genome (47).
Spot-2 80 25 (122) 25 2.91 (↑) Kinesin heavy chain
isoform 5C (KIF5C)
Kinesin motor protein present in motor
neurons and associated with trafficking of
mitochondria and vesicles (48,49).
Spot-3 102 20 (107) 52 2.23 (↑) Annexin A2 (ANXA2) Phospholipid-binding intracellular protein.
Involved in anti-inflammatory and
anticoagulation, cell proliferation and
differentiation and apoptosis (34–36).
Spot-4 90 37 (109) 24 2.82 (↑)
Nebulin-related-ancho-
ring protein (NRAP)
Known for cytoskeletal stability, cell
migration and protein scaffolding (50).
Spot-5 125 14 (67) 53 2.07 (↑) Guanine
nucleotide-binding
protein subunit
beta-2-like 1 (RACK1)
Intracellular adapter protein in
signal-tranuction pathways. Influences
cell proliferation, migration, adhesion and
spreading and protein synthesis (51,52).
Spot-6 100 18 (68) 35 0.33 (↓) Stress-induced
phosphoprotein 1
(STI1)
Co-chaperone in Hsp70 and Hsp90 folding
and protein transcription, signal
transduction and cell division. Associated
with cell proliferation and invasion (53).
Spot-7 93 17 (65) 35 0.66 (↓) Heterogeneous nuclear
ribonucleoprotein L
(hnRNP L)
Central role in RNA metabolism. Also
implicated in cell proliferation and
invasion (54,55).
Spot-8 93 21 (128) 61 0.4 (↓) Phosphoglycerate Kinase
1 (PGK1)
Catayzes production one molecule of ATP
during glicose breackdown (56).
Spot-9 110 14 (72) 48 Only in
NCGl
Aldose reductase (AR) Metabolic reduction of glucose to sorbitol
and catalyzes reduction of ROS and lipid
peroxidation, increasing mutagenesis risk
(57,58).
Spot-10e 79 10 (54) 40 Only in
NCGl
Carbonic anhydrase (CA) Metalloenzyme participating in respiration,
calcification and acid-base balance.
Product of HIF-1α, overexpressed in
hypoxic solid tumors (59,60).
Spot-11d 64 8 (58) 17 Only in
CGl
Citrate synthase,
mitochondrial (CS)
Catalyzes mytochondiral reactions and it is
considered to play role in cancer cells
metabolism regarding metabolic
reprogramming (61,62).
a Scores greater than 77 are significant for p < 0.01
b Represents the percentage of the protein’s sequence represented by the peptides identified in the MS run
c Ratio = CGl/NCGl (CGl – conditioned glioma cells, NCGl – non-conditioned glioma cells)
d Results obtained by limiting the research to entries from Mus musculus. In this case, scores greater than 62 are significant for p < 0.01
e Result obtained allowing up to 2 missed cleavages
This interpretation may be further supported by the increased
expression of mitochondrial citrate synthase. Also, proteome
array profiling reveals under expression of TIMP-1, an inhib-
itor of ECM degradation, Serpin E1 and adiponectin signifi-
cant downregulation in conditioned medium, supporting
adipokine results of carcinogenesis development by
adipocytes.
Additionally, data revealed that aldose reductase and car-
bonic anhydrase were present only in glioma cells and that
their expression was completely blocked when glioma cells
were exposed to mature adipocytes conditioned medium. Our
findings suggested that this blockage may reflect a total inhi-
bition of aldose reductase and carbonic anhydrase, possibly
associated to oxidative stress response prevention, inhibition
of inflammation and cancer proliferation, angiogenesis and
carcinogenesis, which may suggest some kind of protective
mechanism related to obesity.
Considering overexpressed proteins in conditioned medi-
um, RFC1, KIF5C, ANXA2, NRAP, RACK1 results were
supported by overexpression of almost all the proteins profiled
by arrays, comprising angiogenesis, growth, metabolic and
hormonal functions. Our analysis revealed that ANXA2 ex-
pression (2.23 fold) was more pronounced when glioma cells
were exposed to CGl. This finding is in agreement with pre-
vious studies that also revealed that ANXA2 is elevated in
glioma, in which it plays a central role in cell motility, migra-
tion, invasion and angiogenesis (Lokman et al. 2011; Zhai
et al. 2011; Zhang et al. 2012).
Moreover, and considering proteome array profiling,
endocan, which is a proteoglycan secreted by endothelial cells
and upregulated by proangiogenic factors, appears to be
overexpressed in tumour vessels (Maurage et al. 2009;
Matano et al. 2014). Considering its overexpression in CGl,
it may explain the involvement of adipose tissues in tumor
aggressiveness. In addition, adipose tissue contains diverse
cells types including adipose stromal cells, which produce a
myriad of angiogenic factors, VEGF, HGF, FGF-2, and TGF,
contributing to the increment of released angiogenic and
growth factor cytokines.
Thru microarray analysis we further identified the factors
that are released by adipocyte cells, and revealed that several
pro-inflammatory factors (IL-6, IL-11, LIF, PAI-1, TNF-α),
metabolic markers (FGF-21, IGFBPs), angiogenic growth
factors (endocan, HGF, VEGF IGF-I), and hormones (leptin,
resistin, RBP-4) were secreted to the medium into a high ex-
tent, whereas TIMP-1, an inhibitor of ECM degradation,
SerpinE1, which encodes Plasminogen Activator Inhibitor 1
(PAI-1), were under expressed on CGl. Adiponectin, as it was
expectable, was significantly downregulated in CGl medium
when compared with NCGl. Adiponectin modulates inflam-
matory responses, energy expenditure in the CNS and periph-
ery, glucose regulation and fatty acid catabolism. Its circulat-
ing levels inversely correlate with insulin resistance, metabol-
ic syndrome, obesity and cardiovascular diseases. Curiously,
different hormones related with insulin resistance and obesity,
including TNF-α and IL-6, downregulate adiponectin expres-
sion and secretion in fat cells in vitro (Cao 2013; Donohoe
et al. 2016). Our results on TNF-α (adipocytokine implicated
in inflammation, apoptosis and cell survival), IL-6 (related to
proliferation in human glioblastoma cases, leading to poor
prognosis) and IL-11, corroborate these inverse relationship
with adiponectin (Hossain et al. 2015).
Endocan, as well as FGF-21, are extensively present along
with proinflammatory and proangiogenic molecules. It is as-
sociated with a vast number of pathological conditions where
endothelium gets highly vascularized cancers, making it a
likely marker of the vascular growth and angiogenesis during
cancer evolution (Delehedde et al. 2013),(Aoki et al. 2002).
These data support our findings in which endocan is
overexpressed in CGl. Moreover, and regarding other growth
factors, FGF-21, HGF and IGFBPs, they all were
overexpressed in CGl. Hepatocyte Growth Factor (HGF), a
multifunctional trophic factor activates a tyrosine kinase sig-
naling cascade, is elevated in obese adults and adolescents.
In vitro, HGF secretion from adipocytes of obese compared
to lean individuals is greater (Cao 2013; Kiliaan et al. 2014).
Development and basic functions of organs and tissues
relay on angiogenesis, and angiogenesis role in adipose tissue
development and obesity is crucial. Additionally, a great num-
ber of studies point that an insufficiency in adipose tissue
angiogenesis contributes to metabolic disease in obesity
(Lemoine et al. 2013; Corvera and Gealekman 2014). These
Fig. 1 Expression proteomic profile of GL261 with and without the effect of the secretome of 3T3-L1 mature adipocyte cells
data from the literature reinforce our findings concerning the
effect of conditioned medium from adipose tissue in augment-
ing GL261 cell proliferation, migration, ability to invade and
decreasing apoptosis (Fig. 2).
Finally, bioinformatic cancer tools were used for better un-
derstand if the genes and proteins found in our animal model
affected by the molecules secreted by adipocytes could also be
involved in human cancer. First, we queried the Brain Lower
Grade Glioma cohort database from The Cancer Genome
Atlas (TCGA-LGG project) concerning 516 human subjects
using the over-expressed and down-regulated genes found in
our microarray studies. A total of 8 cases (3 males and 5
females) with 15 somatic mutations (mainly substitutions) in
7 of the 10 query genes were found (SERPINE1, IL10,
ICAM1, PITX2, ESM1, RETN and TIMP1) revealing that
they might be somehow implicated in the human cancer.
However, a larger sample size will be required to find statisti-
cally significant effects and to conjecture the impact of these
genes/mutations in glioma overall survival and aggressive-
ness. Then using the same set of over- and down-regulated
genes it was performed an analysis in the REACTOME in
order to understand the involvement of the orthologous
proteins in human pathways. The cross-reference of the sev-
eral differentially expressed markers of glioma under the ef-
fect of the molecules secreted by adipocytes by REACTOME
has result in an outcome involving scientifically more than 25
human pathways (Supplementary Data). In brief, the adipo-
cytes’ secretome may influence mainly cancer signaling trans-
duction, immune/inflammatory, disease (cancer) gene
transcription and extracellular matrix organization human
pathways (Fig. 3).
Concluding remarks
In conclusion, the present study presents a paradoxical rela-
tionship between obesity and cancer (Fig. 3). In a first view,
conditioned medium (adipokines-enriched medium) may
present a protective effect against glioma, since STI1,
hnRNPs and PGK1 that are generally overexpressed in several
types of cancer are under expressed. Similarly, both carbonic
anhydrase and aldose reductase that play an important role in
cell physiology, inflammation and cancermetabolism are even
suppressed in glioma cells that grown under adipokines-
enriched environment.
Fig. 2 Proposed classification of molecules analyzed by microarrays considering its cellular and molecular functions. According to over and under-
expression in different contexts
Contrariwise, RFC1, KIF5C, ANXA2, N-RAP and
RACK1 that are generally involved in the matrix remodeling,
proliferation, migration, invasion of cancer cells is
overexpressed in GL261 cell the in the presence of the
adipokines-enriched medium. Furthermore, along with these
and CG1, and as long as we can observe on protein secretome
assay, our results unfolded the damaging effects of adipocytes
secretome towards glioma aggressiveness. Also, the presence
of citrate synthase only in glioma cells cultured under
conditioned medium and the decreased expression of PGK1
supports the non-tested hypothesis that under an obesity envi-
ronment, glioma cells may reshuffle their metabolic patterns
towards increased lipid consumption for aerobic ATP produc-
tion over glucose and other simple sugars.
Furthermore, our MALDI-TOF and proteomic array data
suggests that, on a primary phase, obesity contributes for de-
creasing of the tumor initiation. Even though, as time goes by,
studied growth factors positively influence proliferation and
Fig. 4 Influence of adipocyte secretome in glioma tumorigenesis. Under the influence of the adipocyte secretome some proteomic alterations promote
tumorigenesis (pink circles) and while other alterations seem to be protective (green circles)
Fig. 3 REACTOME diagram for human ortholog gene pathways. This
figure shows a genome-wide overview regarding the pathways of glioma
altered by adipocyte secretome. Adipocyte secretome influences immune/
inflammatory signaling pathways in human glioma cancer cells. The grey
color code signifies pathways that are not significantly over-represented.
Red and green colors denote significant (p < 0,05) pathways under- and
over-represented respectively
restricted tumorigenic growth. However, as we can ob-
serve from diminished growth and hypoxic factors, and
different metalloproteases, suggesting that previously tu-
mor proliferation due to obesity are restricted and con-
fined, not metastizing. As stated previously, two impor-
tant studies have recognized that obesity has no clear
relationship with the occurrence of glioma (Wiedmann
et al. 2017; Disney-Hogg et al. 2018). Thus, our data
reinforce that idea on obesity as no relation to glioma
and some of the secreted adipokine might even be pro-
tective against glioma initiation and metastization
(Fig. 4). However, once the tumor is stablished, at least
some adipokines might be involved in other stages of
carcinogenesis as summarized in Fig. 4.
Finally, use mouse glioma C57Bl/6 J as a glioma in vivo
model as long as we may growth their cell in vitro for post
in vivo inoculation. This way we may study tissue behavior in
response to cancer cells using a peer-reviewed validated animal
model (Szatmari et al. 2006; Candolfi et al. 2007; Lawrence
et al. 2012; Sielska et al. 2013; YI et al. 2013; Xu et al. 2014).
This study undoubtedly requires additional work to
fulfill our understanding on the implication of adipo-
cytes in malignant brain tumors biology. Meanwhile, it
discloses an interesting in vitro model for the study of
glioma biology under a Bobesity^ environment, that can
be explored for the understanding of cancer cells biolo-
gy, for the search of biomarkers, prognostic markers and
therapeutic approaches.
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